Kinnate Biopharma Inc. announced the appointment of Nima Farzan as Chief Executive Officer, and a member of the Board of Directors. Farzan brings nearly two decades of executive leadership and commercial and development experience in the biopharmaceutical industry to the Kinnate team, most recently as president and CEO of PaxVax. Company co-founder and former CEO Stephen Kaldor, PhD, has been appointed Chairman. Kinnate has also announced the appointment of Mark Meltz as Chief Operating Officer and General Counsel. Meltz joins Kinnate from Audentes Therapeutics where he was Senior Vice President and General Counsel and helped lead the sale of the company to Astellas Pharma in January 2020.